David Armistead

Dr. David Armistead is Entrepreneur-in-Residence at Third Rock Ventures LLC.
Prior to joining Thrid Rock ventures in 2010.
He was with Oxford Bioscience Partners.
He was Vice President and Site Head for the Amgen Cambridge Research Center, where he oversaw all aspects of the East Coast research activities for Amgen Inc. In 1997, he was a co-founder of Kinetix Pharmaceuticals, where he held the position of Vice President of Research and Development and Chief Scientific Officer until the acquisition of Kinetix by Amgen in December 2000.
Previously, he held the position of Head of Immunosuppressive Research and Development and Senior Scientist-Medicinal Chemistry at Vertex Pharmaceuticals.
Prior to that, he held the position of Senior Research Chemist in Inflammation and Immunology at Merck Sharp and Dohme Research Laboratories (Merck & Co., Inc.).
He left Merck to become a founding member of Vertex in 1989.
Dr. Armistead holds a Bachelor of Arts and a Master of Science in Chemistry from Virginia Polytechnic Institute, a Ph.D.
in Synthetic Chemistry from the University of South Carolina and was a National Institutes of Health Postdoctoral Fellow at Yale University.